Piedmont Realty Trust Announces Pricing of Senior Notes Offering - Piedmont Realty Trust ( NYSE:PDM )
Atlanta, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Piedmont Realty Trust, Inc. ( the "Company" or "Piedmont" ) ( NYSE:PDM ) announced today that its operating partnership, Piedmont Operating Partnership, LP ( the "Operating Partnership" ) , has priced an offering of $400 million aggregate principal ...
Piedmont Realty Trust Announces Pricing of Senior Notes Offering
Atlanta, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Piedmont Realty Trust, Inc. ( the "Company" or "Piedmont" ) ( NYSE:PDM ) announced today that its operating partnership, Piedmont Operating Partnership, LP ( the "Operating Partnership" ) , has priced an offering of $400 million aggregate principal ...
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Annexon ( NASDAQ:ANNX )
BRISBANE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( "Annexon" ) ( NASDAQ:ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the ...
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
BRISBANE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( "Annexon" ) ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the ...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Annexon ( NASDAQ:ANNX )
BRISBANE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( NASDAQ:ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has ...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BRISBANE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( NASDAQ: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has ...
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( "Cogent" ) ( NASDAQ:COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten ...
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( "Cogent" ) ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten ...
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - Vor Biopharma ( NASDAQ:VOR )
BOSTON, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Vor Biopharma Inc. ( NASDAQ:VOR ) , a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a ...
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
BOSTON, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Vor Biopharma Inc. ( Nasdaq: VOR ) , a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a ...
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock - Vor Biopharma ( NASDAQ:VOR )
BOSTON, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Vor Biopharma Inc. ( NASDAQ:VOR ) ( Vor Bio ) , a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of ...
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - BillionToOne ( NASDAQ:BLLN )
MENLO PARK, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A ...
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - Benitec Biopharma ( NASDAQ:BNTC )
HAYWARD, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ( "ddRNAi" ) ...
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
HAYWARD, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( Nasdaq: BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ( "ddRNAi" ) ...
BillionToOne Announces Pricing of Upsized Initial Public Offering
MENLO PARK, Calif., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BillionToOne, Inc. ( NASDAQ:BLLN ) , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the pricing of its upsized initial public offering of 4,551,100 shares of ...
BillionToOne Announces Pricing of Upsized Initial Public Offering
MENLO PARK, Calif., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BillionToOne, Inc. ( Nasdaq: BLLN ) , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the pricing of its upsized initial public offering of 4,551,100 shares of ...
Strive Announces Pricing of Upsized Initial Public Offering of SATA Stock
DALLAS, Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Strive, Inc. ( Nasdaq: ASST ) ( "Strive" or the "Company" ) today announced the upsizing and pricing of its initial public offering ( the "offering" ) on November 5, 2025 of 2,000,000 shares of Strive's Variable Rate Series A Perpetual Preferred Stock ...
Benitec Biopharma Inc. Announces Proposed Public Offering
HAYWARD, Calif., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( Nasdaq: BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ( "ddRNAi" ) ...
First Watch Restaurant Group, Inc. Announces Secondary Offering of Common Stock
BRADENTON, Fla., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- First Watch Restaurant Group, Inc. ( "FWRG" or the "Company" ) ( NASDAQ: FWRG ) , the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the launch of an underwritten secondary offering ( the "Offering" ) by ...
First Watch Restaurant Group, Inc. Announces Secondary Offering of Common Stock - First Watch Restaurant Gr ( NASDAQ:FWRG )
BRADENTON, Fla., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- First Watch Restaurant Group, Inc. ( "FWRG" or the "Company" ) ( NASDAQ:FWRG ) , the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the launch of an underwritten secondary offering ( the "Offering" ) by ...
Highwoods Prices $350 Million of 5.350% Notes Due 2033
RALEIGH, N.C., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Highwoods Properties, Inc. ( NYSE: HIW ) ( the "Company" ) announced today that Highwoods Realty Limited Partnership, the operating partnership through which the Company conducts its operations, has priced a $350 million offering of 5.350% ...
Highwoods Prices $350 Million of 5.350% Notes Due 2033 - Highwoods Props ( NYSE:HIW )
RALEIGH, N.C., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Highwoods Properties, Inc. ( NYSE:HIW ) ( the "Company" ) announced today that Highwoods Realty Limited Partnership, the operating partnership through which the Company conducts its operations, has priced a $350 million offering of 5.350% ...
Broadridge's Q1 Earnings and Revenues Outpace Estimates, Rise Y/Y
BR delivers a strong start to fiscal 2026, with earnings up 51% and revenues climbing 11.7%, both topping consensus estimates.
Broadridge Financial Solutions ( BR ) Q1 Earnings and Revenues Top Estimates
Broadridge Financial (BR) delivered earnings and revenue surprises of +26.89% and +3.56%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Kimco Realty® Announces $750 Million ATM Equity Offering Program and $750 Million Stock Repurchase Program
JERICHO, N.Y., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Kimco Realty Corp. ( NYSE: KIM ) ( the "Company" or "Kimco" ) today announced the establishment of an "at the market" continuous offering program, pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per ...
Strive Announces Proposed Initial Public Offering of SATA Stock
DALLAS, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Strive, Inc. ( Nasdaq: ASST ) ( "Strive" or the "Company" ) today announced that, subject to market and other conditions, it intends to conduct an initial public offering ( the "offering" ) registered under the Securities Act of 1933, as amended ( the ...
Broadridge Set to Report Q1 Earnings: What's in the Cards?
BR is likely to gear up to post Q1 fiscal 2026 results, with estimates pointing to strong earnings and revenue growth.
Broadridge Set to Report Q1 Earnings: What's in the Cards?
BR is likely to gear up to post Q1 fiscal 2026 results, with estimates pointing to strong earnings and revenue growth.
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
ZUG, Switzerland, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Oculis Holding AG ( Nasdaq: OCS. XICE: OCS ) ( "Oculis" or the "Company" ) , a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today ...
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
ZUG, Switzerland, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Oculis Holding AG ( Nasdaq: OCS. XICE: OCS ) ( "Oculis" or the "Company" ) , a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today ...
BillionToOne Announces Launch of Initial Public Offering Roadshow
MENLO PARK, Calif., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 ...
BillionToOne Announces Launch of Initial Public Offering Roadshow
MENLO PARK, Calif., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 ...
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the ...
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the ...
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock - RAPT Therapeutics ( NASDAQ:RAPT )
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- RAPT Therapeutics, Inc. ( NASDAQ:RAPT ) ( "RAPT" ) , a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and ...
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- RAPT Therapeutics, Inc. ( Nasdaq: RAPT ) ( "RAPT" ) , a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and ...
Aveanna Announces Pricing of Secondary Offering of Common Stock
ATLANTA, Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Aveanna Healthcare Holdings Inc. ( NASDAQ: AVAH ) , a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today the pricing of the previously announced secondary offering by ...
Aveanna Announces Launch of Secondary Offering of Common Stock
ATLANTA, Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Aveanna Healthcare Holdings Inc. ( NASDAQ: AVAH ) , a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today that certain selling stockholders affiliated with J.H.
Aveanna Announces Launch of Secondary Offering of Common Stock - Aveanna Healthcare Hldgs ( NASDAQ:AVAH )
ATLANTA, Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Aveanna Healthcare Holdings Inc. ( NASDAQ:AVAH ) , a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today that certain selling stockholders affiliated with J.H.
Fintech can supercharge Hong Kong as financial hub: Broadridge CEO
Embracing technology platforms for applications such as electronic proxy voting, private debt underwriting and trading of repurchase (repo) agreements can help Hong Kong elevate its standing as Asia's top financial hub, according to a leading US fintech firm.
Aeroméxico Announces Filing of Amended Registration Statement for Proposed Global Offering
MEXICO CITY, Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Grupo Aeroméxico, S.A.B. de C.V. ( "Aeroméxico" ) today announced the launch of its global offering ( the "Global Offering" ) , consisting of 11,727,325 American Depositary Shares ( "ADSs" ) in the United States and 27,463,590 common shares in ...
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
BOSTON, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - C4 Therapeutics ( NASDAQ:CCCC )
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with ...
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - Spyre Therapeutics ( NASDAQ:SYRE )
WALTHAM, Mass., Oct. 15, 2025 ( GLOBE NEWSWIRE ) -- Spyre Therapeutics, Inc. ( "Spyre" or the "Company" ) ( NASDAQ:SYRE ) , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of ...
Block & Grubhub Team Up to Upgrade Food Ordering Ecosystem
XYZ teams up with Grubhub to streamline restaurant orders and payments, linking Square POS with Cash App Pay for a smoother dining experience.
EyePoint Announces Pricing of Public Offering - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten ...
EyePoint Announces Pricing of Public Offering
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten ...
EyePoint Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an ...
